Guérin R A
C.H.U. Pitié-Salpêtrière, Centre des Tumeurs, Paris.
Rev Mal Respir. 1988;5(2):167-71.
For ten years radiotherapy has had a role in the diminution of local and regional recurrence post-operatively in thymomas. The therapy was for a long time empirical, but today radiotherapy is more standardised: there is a consensus on the methodology of the trajectory and on the optimal doses (50 to 60 gy in 6/7 weeks) according to the volume of tumour remaining. In numerous recent retrospective trials it is apparent that the overall level of survival at 5 years is 46 to 66%. Since 1982 the study group of thymic tumours (GETT) has carried out a prospective trial. It has adopted the same surgical and anatomical classification (table 5) and the same radiotherapy and chemotherapy protocol.
十年来，放射治疗在减少胸腺瘤术后局部和区域复发方面发挥了作用。长期以来，这种治疗方法都是经验性的，但如今放射治疗更加标准化：对于照射轨迹的方法以及根据残留肿瘤体积确定的最佳剂量（6/7周内50至60戈瑞）已达成共识。在最近的许多回顾性试验中，很明显5年总体生存率为46%至66%。自1982年以来，胸腺肿瘤研究组（GETT）开展了一项前瞻性试验。该试验采用了相同的手术和解剖学分类（表5）以及相同的放疗和化疗方案。
